Biocon Limited

BSE: 532523 NSE: BIOCON
Biocon Limited - pharma in Bengaluru, Karnataka, India. FY 2026 financials and compliance.
CIN L24234KA1978PLC003417 Incorporated 29 November 1978 ROC Bangalore HQ Bengaluru, Karnataka, India
Active Listed - NSE: BIOCON · BSE: 532523 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹16,927 Cr
▲ 10.91% YoY
EBITDA · FY 2026
₹3,797.8 Cr
▼ 13.18% YoY
Net profit · FY 2026
₹368.8 Cr
▼ 74.2% YoY
Authorised capital
₹700 Cr
Registered with MCA
Paid-up capital
₹668.48 Cr
Issued & subscribed
Open charges
₹707.63 Cr
Satisfied ₹1,510.35 Cr
Company age
48 yrs
Est. 1978
Employees · EPFO
4,020
Latest available

About Biocon Limited

Data last updated: 23 December 2025

Biocon Limited is a public limited company based in Bengaluru, Karnataka, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 29 November 1978, the company has been in operation for over 48 years.

Registered with ROC Bangalore under CIN L24234KA1978PLC003417. Listed on BSE: 532523 and NSE: BIOCON.

Capital: an authorised share capital of ₹700 Cr and a paid-up capital of ₹668.48 Cr. It is led by directors including Bobby Kanubhai Parikh and Kiran Mazumdar Shaw.

Last AGM: 08 August 2025. Financial statements filed for year ended 31 March 2025. Office: 20Th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100.

As per the financials filed for FY 2025, the company reported a revenue of ₹16,470 Cr, a growth of 5% compared to the previous year.

The company has a workforce of approximately 4,020 employees as per the latest available data. Its group structure includes 6 subsidiaries.

The company is associated with 1 brand - Biocon. As per MCA filings, the company has open charges of ₹707.63 Cr and satisfied charges of ₹1,510.35 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.

Company Details of Biocon Limited
CIN L24234KA1978PLC003417
Registration Number 003417
Incorporation Date 29 November 1978
ROC Bangalore
Listing Status Listed (BSE: 532523, NSE: BIOCON)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Siddharth Mittal Managing Director Kiran Mazumdar Shaw Whole-Time Director Bobby Kanubhai Parikh Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    biocon.com
  • Social Media
  • Registered Address
    20Th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100
  • Industry
    Pharma, Drug Formulation & Development
Company report
Biocon Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Biocon Limited report

Financials, compliance, directors, charges, ownership and filings for Biocon Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Biocon Limited

Biocon Limited has one previous CIN (Corporate Identification Number): L00309KA1978PLC003417. The current CIN is L24234KA1978PLC003417, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24234KA1978PLC003417 Current
L00309KA1978PLC003417 Previous

Associated Brands with Biocon Limited

Biocon Limited operates one associated brand: Biocon. These brands represent Biocon Limited's diversified market presence and brand portfolio.

Brand Description Website
Biocon
Drug R&D services are provided for multiple therapeutic areas. biocon.com

Business Activity of Biocon Limited

Biocon Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Biocon Limited

Biocon Limited is audited by BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Biocon Limited

Biocon Limited is currently managed by 11 directors, with 26 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Bobby Kanubhai Parikh
Also directs: Avaana Capital Advisors Llp, Hindustan Unilever Limited, Indostar Capital Finance Limited and 4 more
Director 27 Jul 2018 7 Years 11 Months Current
Kiran Mazumdar Shaw
Also directs: Biocon Biologics Limited, Glenloch Properties Llp, Trent Limited and 5 more
Whole-Time Director 01 Apr 2010 16 Years 3 Months Current
Siddharth Mittal
Also directs: Biocon Pharma Limited, Biocon Biosphere Limited, Biocon Academy
Managing Director 01 Dec 2019 6 Years 7 Months Current
Eric Vivek Mazumdar Director 01 Nov 2021 4 Years 8 Months Current
Naina Lal Kidwai
Also directs: Upl Limited, Gland Pharma Ltd, Nayara Energy Limited and 1 more
Director 28 Apr 2022 4 Years 2 Months Current
Rekha Mehrotra Menon Director 26 Jul 2023 2 Years 11 Months Current
Showing 6 of 11 current directors. View all directors

Financials of Biocon Limited FY 2026 filings available

Biocon Limited reported revenue of ₹16,927 Cr (up 10.91% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹16,927 Cr ▲ 10.91%
Profit · FY 2026
₹368.8 Cr ▼ 74.2%
EBITDA · FY 2026
₹3,797.8 Cr ▼ 13.18%
Revenue₹ Cr · Consolidated010,00020,000FY 2020: ₹6,367 Cr6,367FY 2020FY 2021: ₹7,106 Cr · +11.6% YoY7,106+11.6%FY 2021FY 2022: ₹8,184 Cr · +15.2% YoY8,184+15.2%FY 2022FY 2023: ₹11,174 Cr · +36.5% YoY11,174+36.5%FY 2023FY 2024: ₹14,756 Cr · +32.1% YoY14,756+32.1%FY 2024FY 2025: ₹15,262 Cr · +3.4% YoY15,262+3.4%FY 2025FY 2026: ₹16,927 Cr · +10.9% YoY16,927+10.9%FY 2026
Net Profit₹ Cr · Consolidated05001,0001,500FY 2020: ₹871 Cr871FY 2020FY 2021: ₹846 Cr · -2.8% YoY846-2.8%FY 2021FY 2022: ₹772 Cr · -8.8% YoY772-8.8%FY 2022FY 2023: ₹643 Cr · -16.7% YoY643-16.7%FY 2023FY 2024: ₹1,298 Cr · +101.8% YoY1,298+101.8%FY 2024FY 2025: ₹1,429 Cr · +10.1% YoY1,429+10.1%FY 2025FY 2026: ₹369 Cr · -74.2% YoY369-74.2%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02,0004,0006,000Q1'25: ₹3,433 Cr · +0.3% YoY3,433+0.3%Q1'25Q2'25: ₹3,590 Cr · +3.7% YoY3,590+3.7%Q2'25Q3'25: ₹3,821 Cr · -3.3% YoY3,821-3.3%Q3'25Q4'25: ₹4,417 Cr · +12.8% YoY4,417+12.8%Q4'25Q1'26: ₹3,942 Cr · +14.8% YoY3,942+14.8%Q1'26Q2'26: ₹4,296 Cr · +19.6% YoY4,296+19.6%Q2'26Q3'26: ₹4,173 Cr · +9.2% YoY4,173+9.2%Q3'26Q4'26: ₹4,517 Cr · +2.3% YoY4,517+2.3%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹16,927 Cr ₹15,262 Cr ₹14,756 Cr ₹11,174 Cr ₹8,184 Cr ₹7,105.8 Cr ₹6,367.2 Cr
Other Income ₹342.5 Cr ₹1,208.2 Cr ₹865.5 Cr ₹375.9 Cr ₹212.7 Cr ₹254.5 Cr ₹161.4 Cr
Total Income ₹17,270 Cr ₹16,470 Cr ₹15,621 Cr ₹11,550 Cr ₹8,396.7 Cr ₹7,360.3 Cr ₹6,528.6 Cr
Cost of Materials Consumed ₹5,277.6 Cr ₹4,276.7 Cr ₹5,071.9 Cr ₹3,191.1 Cr ₹2,813.9 Cr ₹2,430.2 Cr ₹2,167.6 Cr
Purchases of Stock-in-Trade ₹1,362.6 Cr ₹626.6 Cr ₹682.7 Cr ₹626.1 Cr ₹161.1 Cr ₹68.4 Cr ₹85.4 Cr
Changes in Inventories -₹949.5 Cr ₹294.2 Cr -₹856.7 Cr -₹154.1 Cr -₹256.6 Cr -₹290.1 Cr -₹200.8 Cr
Employee Benefit Expense ₹3,508 Cr ₹3,144.4 Cr ₹2,664.1 Cr ₹2,181 Cr ₹1,880.1 Cr ₹1,741 Cr ₹1,458.8 Cr
Finance Costs ₹990.3 Cr ₹897.4 Cr ₹974.4 Cr ₹419 Cr ₹67.6 Cr ₹57.7 Cr ₹64.9 Cr
Depreciation & Amortisation ₹1,956.7 Cr ₹1,687 Cr ₹1,568.8 Cr ₹1,113.1 Cr ₹814.2 Cr ₹715.1 Cr ₹552.2 Cr
Other Expenses ₹4,273 Cr ₹3,753.5 Cr ₹3,895 Cr ₹2,818.4 Cr ₹1,615.3 Cr ₹1,503.7 Cr ₹1,253.1 Cr
Total Expenses ₹16,419 Cr ₹14,680 Cr ₹14,000 Cr ₹10,195 Cr ₹7,095.6 Cr ₹6,226 Cr ₹5,381.2 Cr
Profit Before Exceptional Items & Tax ₹850.8 Cr ₹1,790.1 Cr ₹1,621 Cr ₹1,355.5 Cr ₹1,301.1 Cr ₹1,134.3 Cr ₹1,147.4 Cr
Exceptional Items -₹402.9 Cr ₹96.5 Cr -₹11.6 Cr -₹291.4 Cr -₹111.1 Cr ₹12.6 Cr ₹67.5 Cr
Profit Before Tax ₹447.9 Cr ₹1,886.6 Cr ₹1,609.4 Cr ₹1,064.1 Cr ₹1,190 Cr ₹1,146.9 Cr ₹1,214.9 Cr
Total Tax Expense ₹79.1 Cr ₹457.2 Cr ₹227.4 Cr ₹254.1 Cr ₹211.5 Cr ₹221.5 Cr ₹315.1 Cr
Net Profit ₹368.8 Cr ₹1,429.4 Cr ₹1,297.8 Cr ₹643 Cr ₹771.6 Cr ₹846.2 Cr ₹870.9 Cr
  attributable to Owners ₹385.6 Cr ₹1,013.3 Cr ₹1,022.5 Cr ₹462.7 Cr ₹648.4 Cr ₹740.5 Cr ₹748.2 Cr
  attributable to NCI -₹16.8 Cr ₹416.1 Cr ₹275.3 Cr ₹180.3 Cr ₹123.2 Cr ₹105.7 Cr ₹122.7 Cr
Other Comprehensive Income ₹2,044.3 Cr ₹436.7 Cr ₹386.7 Cr ₹76.6 Cr ₹110.2 Cr ₹214.5 Cr -₹188.4 Cr
Total Comprehensive Income ₹2,413.1 Cr ₹1,866.1 Cr ₹1,684.5 Cr ₹719.6 Cr ₹881.8 Cr ₹1,060.7 Cr ₹682.5 Cr
EBITDA (computed) ₹3,797.8 Cr ₹4,374.5 Cr ₹4,164.2 Cr ₹2,887.6 Cr ₹2,182.9 Cr ₹1,907.1 Cr ₹1,764.5 Cr
Basic EPS ₹2.82 ₹8.46 ₹8.55 ₹3.88 ₹5.44 ₹6.32 ₹6.32
Diluted EPS ₹2.82 ₹8.46 ₹8.54 ₹3.87 ₹5.42 ₹6.27 ₹6.30
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹63,651 Cr ₹58,797 Cr ₹56,071 Cr ₹52,043 Cr
Non-current Assets ₹46,471 Cr ₹42,511 Cr ₹40,892 Cr ₹39,709 Cr
Current Assets ₹17,180 Cr ₹16,286 Cr ₹15,179 Cr ₹12,334 Cr
Property, Plant & Equipment ₹9,472.8 Cr ₹8,708.2 Cr ₹7,418.1 Cr ₹7,535.1 Cr
Inventories ₹6,085.7 Cr ₹4,931.1 Cr ₹4,943.9 Cr ₹4,243.7 Cr
Trade Receivables ₹5,986.8 Cr ₹5,487.9 Cr ₹6,230.6 Cr ₹3,573.2 Cr
Cash & Equivalents ₹2,416.5 Cr ₹3,227.1 Cr ₹1,233.6 Cr ₹1,323.5 Cr
Equity (Net Worth) ₹36,622 Cr ₹27,713 Cr ₹25,275 Cr ₹22,489 Cr
Equity Share Capital ₹810.5 Cr ₹600.3 Cr ₹600.3 Cr ₹600.3 Cr
Borrowings (Non-current) ₹10,746 Cr ₹12,405 Cr ₹12,932 Cr ₹15,291 Cr
Borrowings (Current) ₹4,078.4 Cr ₹5,350.1 Cr ₹2,797.2 Cr ₹2,480.2 Cr
Total Debt (computed) ₹14,825 Cr ₹17,756 Cr ₹15,730 Cr ₹17,771 Cr
Current Liabilities ₹14,069 Cr ₹14,334 Cr ₹15,359 Cr ₹8,510.7 Cr
Total Liabilities ₹27,029 Cr ₹31,085 Cr ₹30,796 Cr ₹29,554 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,994 Cr ₹4,061.2 Cr ₹2,953.9 Cr ₹1,852.5 Cr ₹1,176.6 Cr
Investing Cash Flow -₹2,082.1 Cr -₹234.1 Cr -₹1,004.5 Cr -₹14,282 Cr -₹1,699.1 Cr
Financing Cash Flow -₹923.6 Cr -₹1,854 Cr -₹2,332.7 Cr ₹13,049 Cr ₹242.1 Cr
Capital Expenditure ₹1,797.9 Cr ₹2,136.6 Cr ₹1,680.5 Cr ₹1,596 Cr ₹1,697.8 Cr
Free Cash Flow (computed) ₹196.1 Cr ₹1,924.6 Cr ₹1,273.4 Cr ₹256.5 Cr -₹521.2 Cr
Dividends Paid ₹90.8 Cr ₹82.9 Cr ₹203 Cr ₹71.8 Cr -₹346.1 Cr
Net Change in Cash -₹812.3 Cr ₹2,004.3 Cr -₹380.4 Cr ₹641.1 Cr -₹277.1 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹4,516.6 Cr ₹4,173 Cr ₹4,295.5 Cr ₹3,941.9 Cr ₹4,417 Cr ₹3,821.4 Cr ₹3,590.4 Cr ₹3,432.9 Cr ₹3,917.1 Cr ₹3,953.7 Cr ₹3,462.3 Cr ₹3,422.6 Cr
Other Income ₹52.5 Cr ₹117.3 Cr ₹93 Cr ₹79.7 Cr ₹36.9 Cr ₹34.8 Cr ₹32.5 Cr ₹1,134.5 Cr ₹48.6 Cr ₹565.5 Cr ₹157.9 Cr ₹93.5 Cr
Total Income ₹4,569.1 Cr ₹4,290.3 Cr ₹4,388.5 Cr ₹4,021.6 Cr ₹4,453.9 Cr ₹3,856.2 Cr ₹3,622.9 Cr ₹4,567.4 Cr ₹3,965.7 Cr ₹4,519.2 Cr ₹3,620.2 Cr ₹3,516.1 Cr
Cost of Materials Consumed ₹1,358.8 Cr ₹1,327.3 Cr ₹1,367.5 Cr ₹1,224 Cr ₹1,114.2 Cr ₹1,293 Cr ₹1,009.4 Cr ₹860.1 Cr ₹1,477.8 Cr ₹1,402.5 Cr ₹1,166 Cr ₹1,025.6 Cr
Purchases of Stock-in-Trade ₹222.6 Cr ₹167.9 Cr ₹135 Cr ₹837.1 Cr ₹83.5 Cr ₹85.5 Cr ₹49.1 Cr ₹408.5 Cr -₹10 Lakh ₹33.3 Cr ₹372 Cr ₹277.5 Cr
Changes in Inventories -₹182.1 Cr -₹155.9 Cr ₹44.5 Cr -₹656 Cr ₹275.2 Cr -₹19.2 Cr ₹124.1 Cr -₹85.9 Cr -₹148.2 Cr -₹204 Cr -₹411 Cr -₹93.5 Cr
Employee Benefit Expense ₹912.1 Cr ₹875.1 Cr ₹887.7 Cr ₹833.1 Cr ₹811.1 Cr ₹788.3 Cr ₹789.6 Cr ₹755.4 Cr ₹741.6 Cr ₹720.8 Cr ₹622.4 Cr ₹579.3 Cr
Finance Costs ₹231.5 Cr ₹209.9 Cr ₹272.2 Cr ₹276.7 Cr ₹212.4 Cr ₹223.4 Cr ₹225.6 Cr ₹236 Cr ₹227 Cr ₹266.7 Cr ₹247.7 Cr ₹233 Cr
Depreciation & Amortisation ₹513.4 Cr ₹515.3 Cr ₹473 Cr ₹455 Cr ₹436.3 Cr ₹425.4 Cr ₹419.9 Cr ₹405.4 Cr ₹407 Cr ₹414.5 Cr ₹389.3 Cr ₹358 Cr
Other Expenses ₹1,184.9 Cr ₹1,125.1 Cr ₹1,025.4 Cr ₹954.8 Cr ₹1,054.8 Cr ₹922 Cr ₹932.8 Cr ₹874.4 Cr ₹930.1 Cr ₹1,074.3 Cr ₹971.3 Cr ₹919.3 Cr
Total Expenses ₹4,241.2 Cr ₹4,064.7 Cr ₹4,205.3 Cr ₹3,924.7 Cr ₹3,987.5 Cr ₹3,718.4 Cr ₹3,550.5 Cr ₹3,453.9 Cr ₹3,635.2 Cr ₹3,708.1 Cr ₹3,357.7 Cr ₹3,299.2 Cr
Profit Before Exceptional Items & Tax ₹327.9 Cr ₹225.6 Cr ₹183.2 Cr ₹96.9 Cr ₹466.4 Cr ₹137.8 Cr ₹72.4 Cr ₹1,113.5 Cr ₹330.5 Cr ₹811.1 Cr ₹262.5 Cr ₹216.9 Cr
Exceptional Items -₹80.4 Cr -₹293.4 Cr -₹11.9 Cr ₹0 ₹20.4 Cr ₹18.1 Cr ₹26 Cr ₹32 Cr -₹8.8 Cr ₹21.2 Cr -₹24 Cr ₹0
Profit Before Tax ₹247.5 Cr -₹67.8 Cr ₹171.3 Cr ₹96.9 Cr ₹486.8 Cr ₹155.9 Cr ₹98.4 Cr ₹1,145.5 Cr ₹321.7 Cr ₹832.3 Cr ₹238.5 Cr ₹216.9 Cr
Total Tax Expense ₹48.9 Cr -₹16 Cr ₹38.5 Cr ₹7.7 Cr ₹27.4 Cr ₹74.8 Cr ₹71.3 Cr ₹283.7 Cr ₹96.1 Cr ₹54.9 Cr ₹41.6 Cr ₹34.8 Cr
Net Profit ₹198.6 Cr -₹51.8 Cr ₹132.8 Cr ₹89.2 Cr ₹459.4 Cr ₹81.1 Cr ₹27.1 Cr ₹861.8 Cr ₹222.9 Cr ₹753.3 Cr ₹172.7 Cr ₹148.9 Cr
  attributable to Owners ₹125.9 Cr ₹143.8 Cr ₹84.5 Cr ₹31.4 Cr ₹344.5 Cr ₹25.1 Cr -₹16 Cr ₹659.7 Cr ₹135.5 Cr ₹660 Cr ₹125.6 Cr ₹101.4 Cr
  attributable to NCI ₹72.7 Cr -₹195.6 Cr ₹48.3 Cr ₹57.8 Cr ₹114.9 Cr ₹56 Cr ₹43.1 Cr ₹202.1 Cr ₹87.4 Cr ₹93.3 Cr ₹47.1 Cr ₹47.5 Cr
Other Comprehensive Income ₹974.3 Cr ₹305.7 Cr ₹969.8 Cr -₹205.5 Cr -₹183.8 Cr ₹56.6 Cr ₹522.3 Cr ₹41.6 Cr -₹17.2 Cr ₹42.7 Cr ₹190.3 Cr ₹170.9 Cr
Total Comprehensive Income ₹1,172.9 Cr ₹253.9 Cr ₹1,102.6 Cr -₹116.3 Cr ₹275.6 Cr ₹137.7 Cr ₹549.4 Cr ₹903.4 Cr ₹205.7 Cr ₹796 Cr ₹363 Cr ₹319.8 Cr
EBITDA (computed) ₹1,072.8 Cr ₹950.8 Cr ₹928.4 Cr ₹828.6 Cr ₹1,115.1 Cr ₹786.6 Cr ₹717.9 Cr ₹1,754.9 Cr ₹964.5 Cr ₹1,492.3 Cr ₹899.5 Cr ₹807.9 Cr
Basic EPS ₹0.79 ₹1.08 ₹0.66 ₹0.26 ₹2.88 ₹0.21 ₹-0.13 ₹5.51 ₹1.13 ₹5.52 ₹1.05 ₹0.85
Diluted EPS ₹0.79 ₹1.07 ₹0.65 ₹0.26 ₹2.87 ₹0.21 ₹-0.13 ₹5.51 ₹1.13 ₹5.51 ₹1.05 ₹0.85
Latest 12 quarters shown of 25 on record.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Generics ₹846.7 Cr -₹12.3 Cr ₹8,992.6 Cr ₹3,756.1 Cr
Biosimilars ₹2,755.6 Cr ₹147.9 Cr ₹47,888 Cr ₹21,179 Cr
CRDMO ₹1,036.5 Cr ₹202 Cr ₹7,054.9 Cr ₹2,214.7 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Generics ₹3,168.1 Cr -₹134.8 Cr - -
Biosimilars ₹10,431 Cr ₹587.6 Cr - -
CRDMO ₹3,738.7 Cr ₹487.5 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,346.4 Cr ₹2,242.6 Cr ₹2,127.3 Cr ₹1,992.9 Cr ₹1,738.2 Cr ₹2,028.4 Cr ₹1,988.4 Cr
Other Income ₹319.7 Cr ₹242.3 Cr ₹193 Cr ₹271.4 Cr ₹187.2 Cr ₹150.2 Cr ₹201.7 Cr
Total Income ₹2,666.1 Cr ₹2,484.9 Cr ₹2,320.3 Cr ₹2,264.3 Cr ₹1,925.4 Cr ₹2,178.6 Cr ₹2,190.1 Cr
Cost of Materials Consumed ₹1,142.4 Cr ₹1,085.4 Cr ₹1,033.3 Cr ₹978.9 Cr ₹912.3 Cr ₹760.7 Cr ₹858.2 Cr
Purchases of Stock-in-Trade ₹45.2 Cr ₹0 ₹50 Lakh ₹2.1 Cr ₹1.7 Cr ₹90 Lakh ₹90 Lakh
Changes in Inventories -₹118.7 Cr -₹54.6 Cr -₹99.1 Cr ₹3.2 Cr -₹105.8 Cr ₹36.7 Cr -₹31.4 Cr
Employee Benefit Expense ₹467.2 Cr ₹501.3 Cr ₹452.3 Cr ₹433.8 Cr ₹367.7 Cr ₹390.2 Cr ₹344.8 Cr
Finance Costs ₹142.4 Cr ₹236.9 Cr ₹198.8 Cr ₹69.6 Cr ₹40 Lakh ₹40 Lakh ₹1.2 Cr
Depreciation & Amortisation ₹137.3 Cr ₹127.8 Cr ₹121.1 Cr ₹116.9 Cr ₹108.2 Cr ₹103.5 Cr ₹98 Cr
Other Expenses ₹584.2 Cr ₹534.7 Cr ₹477.6 Cr ₹551.4 Cr ₹501.2 Cr ₹527.4 Cr ₹529.9 Cr
Total Expenses ₹2,400 Cr ₹2,431.5 Cr ₹2,184.5 Cr ₹2,155.9 Cr ₹1,785.7 Cr ₹1,819.8 Cr ₹1,801.6 Cr
Profit Before Exceptional Items & Tax ₹266.1 Cr ₹53.4 Cr ₹135.8 Cr ₹108.4 Cr ₹139.7 Cr ₹358.8 Cr ₹388.5 Cr
Exceptional Items -₹215.1 Cr ₹607.5 Cr ₹14.5 Cr ₹2,862.8 Cr ₹0 ₹0 ₹159.7 Cr
Profit Before Tax ₹51 Cr ₹660.9 Cr ₹150.3 Cr ₹2,971.2 Cr ₹139.7 Cr ₹358.8 Cr ₹548.2 Cr
Total Tax Expense ₹13.8 Cr ₹51.6 Cr ₹31 Cr ₹122.8 Cr ₹53.6 Cr ₹78.3 Cr ₹111.9 Cr
Net Profit ₹37.2 Cr ₹609.3 Cr ₹119.3 Cr ₹2,848.4 Cr ₹86.1 Cr ₹280.5 Cr ₹440.9 Cr
Other Comprehensive Income -₹19.2 Cr -₹12.4 Cr -₹70 Lakh ₹90 Lakh ₹8 Cr ₹2.4 Cr -₹7.7 Cr
Total Comprehensive Income ₹18 Cr ₹596.9 Cr ₹118.6 Cr ₹2,849.3 Cr ₹94.1 Cr ₹282.9 Cr ₹433.2 Cr
EBITDA (computed) ₹545.8 Cr ₹418.1 Cr ₹455.7 Cr ₹294.9 Cr ₹248.3 Cr ₹462.7 Cr ₹487.7 Cr
Basic EPS ₹0.27 ₹5.09 ₹1.00 ₹23.87 ₹0.72 ₹2.36 ₹3.68
Diluted EPS ₹0.27 ₹5.09 ₹1.00 ₹23.82 ₹0.72 ₹2.34 ₹3.67
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹29,271 Cr ₹15,621 Cr ₹13,768 Cr ₹13,030 Cr
Non-current Assets ₹26,983 Cr ₹13,451 Cr ₹11,008 Cr ₹10,464 Cr
Current Assets ₹2,288 Cr ₹2,170.2 Cr ₹2,760 Cr ₹2,566 Cr
Property, Plant & Equipment ₹1,280.9 Cr ₹1,003.8 Cr ₹846.3 Cr ₹842.5 Cr
Inventories ₹875.1 Cr ₹836.3 Cr ₹664.7 Cr ₹560.1 Cr
Trade Receivables ₹1,003.1 Cr ₹829.4 Cr ₹1,048.1 Cr ₹658 Cr
Cash & Equivalents ₹91.4 Cr ₹249.5 Cr ₹122.3 Cr ₹196.6 Cr
Equity (Net Worth) ₹27,080 Cr ₹11,524 Cr ₹10,912 Cr ₹10,916 Cr
Equity Share Capital ₹810.5 Cr ₹600.3 Cr ₹600.3 Cr ₹600.3 Cr
Borrowings (Non-current) ₹93.5 Cr ₹2,251.5 Cr ₹2,040.8 Cr ₹1,297.7 Cr
Borrowings (Current) ₹1,056.8 Cr ₹619.5 Cr ₹0 ₹0
Total Debt (computed) ₹1,150.3 Cr ₹2,871 Cr ₹2,040.8 Cr ₹1,297.7 Cr
Current Liabilities ₹1,965.4 Cr ₹1,737.2 Cr ₹691.2 Cr ₹698 Cr
Total Liabilities ₹2,190.8 Cr ₹4,096.7 Cr ₹2,855.9 Cr ₹2,113.9 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹180.1 Cr ₹621.1 Cr -₹123.2 Cr ₹219.3 Cr ₹47.6 Cr
Investing Cash Flow -₹6,581.7 Cr -₹989 Cr -₹296.4 Cr -₹1,177.8 Cr -₹305.6 Cr
Financing Cash Flow ₹6,602 Cr ₹494.8 Cr ₹343.6 Cr ₹1,039.4 Cr ₹112 Cr
Capital Expenditure ₹283 Cr ₹317.4 Cr ₹301.7 Cr ₹261.9 Cr ₹239.2 Cr
Free Cash Flow (computed) -₹463.1 Cr ₹303.7 Cr -₹424.9 Cr -₹42.6 Cr -₹191.6 Cr
Dividends Paid ₹66.8 Cr ₹60 Cr ₹180.1 Cr ₹60 Cr ₹0
Net Change in Cash -₹158.1 Cr ₹127.2 Cr -₹74.3 Cr ₹85.6 Cr -₹142.5 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹604.7 Cr ₹621.3 Cr ₹583.3 Cr ₹537.1 Cr ₹643.8 Cr ₹562.8 Cr ₹525.4 Cr ₹510.6 Cr ₹532.6 Cr ₹562.8 Cr ₹518.7 Cr ₹513.2 Cr
Other Income ₹49.8 Cr ₹74.8 Cr ₹133.8 Cr ₹61.3 Cr ₹62.7 Cr ₹64.2 Cr ₹73.5 Cr ₹41.9 Cr ₹38.9 Cr ₹48.5 Cr ₹69.6 Cr ₹36 Cr
Total Income ₹654.5 Cr ₹696.1 Cr ₹717.1 Cr ₹598.4 Cr ₹706.5 Cr ₹627 Cr ₹598.9 Cr ₹552.5 Cr ₹571.5 Cr ₹611.3 Cr ₹588.3 Cr ₹549.2 Cr
Cost of Materials Consumed ₹246.1 Cr ₹287.6 Cr ₹320.7 Cr ₹288 Cr ₹322.4 Cr ₹276.8 Cr ₹263 Cr ₹223.2 Cr ₹217.7 Cr ₹264.4 Cr ₹291.5 Cr ₹259.7 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹24.1 Cr ₹21.1 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹20 Lakh ₹30 Lakh ₹0
Changes in Inventories ₹29.5 Cr -₹15.5 Cr -₹78.4 Cr -₹54.3 Cr -₹6 Cr -₹12.9 Cr -₹26 Cr -₹9.7 Cr ₹31.8 Cr -₹16.1 Cr -₹75.6 Cr -₹39.2 Cr
Employee Benefit Expense ₹93.6 Cr ₹121.7 Cr ₹126.2 Cr ₹125.7 Cr ₹124.3 Cr ₹131.9 Cr ₹125.4 Cr ₹119.7 Cr ₹116.8 Cr ₹117.6 Cr ₹112.5 Cr ₹105.4 Cr
Finance Costs ₹16.7 Cr ₹2.3 Cr ₹67.2 Cr ₹56.2 Cr ₹56.7 Cr ₹65.3 Cr ₹59.7 Cr ₹55.2 Cr ₹39.5 Cr ₹56 Cr ₹55 Cr ₹48.3 Cr
Depreciation & Amortisation ₹36.2 Cr ₹34 Cr ₹33.8 Cr ₹33.3 Cr ₹33 Cr ₹33.8 Cr ₹30.5 Cr ₹30.5 Cr ₹29.8 Cr ₹30.9 Cr ₹30.6 Cr ₹29.8 Cr
Other Expenses ₹156.2 Cr ₹154.2 Cr ₹137.8 Cr ₹136 Cr ₹141.1 Cr ₹135.7 Cr ₹125.4 Cr ₹132.5 Cr ₹114.1 Cr ₹125.4 Cr ₹122.8 Cr ₹115.3 Cr
Total Expenses ₹578.3 Cr ₹584.3 Cr ₹631.4 Cr ₹606 Cr ₹671.5 Cr ₹630.6 Cr ₹578 Cr ₹551.4 Cr ₹549.7 Cr ₹578.4 Cr ₹537.1 Cr ₹519.3 Cr
Profit Before Exceptional Items & Tax ₹76.2 Cr ₹111.8 Cr ₹85.7 Cr -₹7.6 Cr ₹35 Cr -₹3.6 Cr ₹20.9 Cr ₹1.1 Cr ₹21.8 Cr ₹32.9 Cr ₹51.2 Cr ₹29.9 Cr
Exceptional Items -₹18.8 Cr -₹196.3 Cr ₹0 ₹0 ₹0 ₹607.5 Cr ₹0 ₹0 ₹0 ₹0 -₹5.2 Cr ₹19.7 Cr
Profit Before Tax ₹57.4 Cr -₹84.5 Cr ₹85.7 Cr -₹7.6 Cr ₹35 Cr ₹603.9 Cr ₹20.9 Cr ₹1.1 Cr ₹21.8 Cr ₹32.9 Cr ₹46 Cr ₹49.6 Cr
Total Tax Expense ₹6.4 Cr -₹8.1 Cr ₹14.8 Cr ₹70 Lakh ₹13.8 Cr ₹19.9 Cr ₹17.7 Cr ₹20 Lakh ₹7.8 Cr ₹8.9 Cr ₹11.3 Cr ₹3 Cr
Net Profit ₹51 Cr -₹76.4 Cr ₹70.9 Cr -₹8.3 Cr ₹21.2 Cr ₹584 Cr ₹3.2 Cr ₹90 Lakh ₹14 Cr ₹24 Cr ₹34.7 Cr ₹46.6 Cr
Other Comprehensive Income -₹12.1 Cr -₹1.4 Cr ₹90 Lakh -₹6.6 Cr -₹3.6 Cr -₹8.2 Cr ₹1.7 Cr -₹2.3 Cr ₹1.1 Cr -₹2.7 Cr -₹2.8 Cr ₹3.7 Cr
Total Comprehensive Income ₹38.9 Cr -₹77.8 Cr ₹71.8 Cr -₹14.9 Cr ₹17.6 Cr ₹575.8 Cr ₹4.9 Cr -₹1.4 Cr ₹15.1 Cr ₹21.3 Cr ₹31.9 Cr ₹50.3 Cr
EBITDA (computed) ₹129.1 Cr ₹148.1 Cr ₹186.7 Cr ₹81.9 Cr ₹124.7 Cr ₹95.5 Cr ₹111.1 Cr ₹86.8 Cr ₹91.1 Cr ₹119.8 Cr ₹136.8 Cr ₹108 Cr
Basic EPS ₹0.32 ₹-0.57 ₹0.55 ₹-0.07 ₹0.18 ₹4.88 ₹0.03 ₹0.01 ₹0.12 ₹0.20 ₹0.29 ₹0.39
Diluted EPS ₹0.32 ₹-0.57 ₹0.55 ₹-0.07 ₹0.18 ₹4.87 ₹0.03 ₹0.01 ₹0.12 ₹0.20 ₹0.29 ₹0.39
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Biocon Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Biocon Limited

As per the shareholding pattern filed with NSE for the quarter ended Jun 2026, promoters hold 44.68%, foreign institutional investors hold 8.16%, domestic institutional investors hold 23.37%, retail and other public shareholders hold 23.74% of Biocon Limited. The company had 392,509 shareholders on record.

Promoters: 44.68%DII (Domestic Institutional): 23.37%FII (Foreign Institutional): 8.16%Retail & Others: 23.74%
Jun 2026
QUARTER
44.68% Promoters
23.37% DII (Domestic Institutional)
8.16% FII (Foreign Institutional)
23.74% Retail & Others
Promoter holding - history
Now 44.68% · Jun 2026High 60.72% · Dec 2015Low 44.68% · Jun 2026
43%47.8%52.5%57.3%62%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 60.72%Mar 2016: 60.72%Jun 2016: 60.68%Sep 2016: 60.68%Dec 2016: 60.68%Mar 2017: 60.68%Jun 2017: 60.67%Sep 2017: 60.67%Dec 2017: 60.67%Mar 2018: 60.67%Jun 2018: 60.67%Sep 2018: 60.67%Dec 2018: 60.67%Mar 2019: 60.67%Jun 2019: 60.67%Sep 2019: 60.67%Dec 2019: 60.67%Mar 2020: 60.67%Jun 2020: 60.67%Sep 2020: 60.67%Dec 2020: 60.67%Mar 2021: 60.67%Jun 2021: 60.64%Sep 2021: 60.64%Dec 2021: 60.64%Mar 2022: 60.64%Jun 2022: 60.64%Sep 2022: 60.64%Dec 2022: 60.64%Mar 2023: 60.64%Jun 2023: 60.64%Sep 2023: 60.64%Dec 2023: 60.64%Mar 2024: 60.64%Jun 2024: 60.64%Sep 2024: 60.64%Dec 2024: 60.64%Mar 2025: 60.64%Jun 2025: 54.45%Sep 2025: 54.45%Dec 2025: 54.45%Jan 2026: 44.91%Mar 2026: 44.91%Jun 2026: 44.68%60.72%44.68%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Jan 2026Dec 2025Sep 2025Jun 2025
Promoters44.68%44.91%44.91%54.45%54.45%54.45%
Public55.27%55.00%54.99%45.43%45.41%45.37%
Employee Trusts0.05%0.09%0.10%0.12%0.14%0.18%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters44.91%60.64%60.64%60.64%60.64%60.67%60.67%60.67%60.67%60.68%60.72%
Public55.00%39.15%39.05%38.81%38.74%38.40%38.10%37.90%37.83%37.55%37.35%
Employee Trusts0.09%0.21%0.32%0.55%0.63%0.93%1.23%1.43%1.50%1.76%1.94%
Promoter change (YoY, %pts)-15.73+0.00+0.00+0.00-0.03+0.00+0.00+0.00-0.01-0.04-

Board & Governance of Biocon Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Biocon Limited has 9 directors - 5 independent and 2 executive. The board is chaired by Kiran Mazumdar Shaw.

DirectorPositionOn board sinceListed boards
Kiran Mazumdar Shaw Executive Director · Chairperson 2010-04-01 4
Siddhath Mittal Executive Director · CEO-MD 2019-12-01 1
Ravi Rasendra Mazumdar Non-Executive - Non Independent Director 2000-08-08 1
Eric Mazumdar Non-Executive - Non Independent Director 2021-11-01 1
Bobby Kanubhai Parikh Non-Executive - Independent Director 2018-07-27 4
Naina Lal Kidwai Non-Executive - Independent Director 2022-04-28 3
Rekha Mehrotra Menon Non-Executive - Independent Director 2023-07-26 1
Nicholas Robert Haggar Non-Executive - Independent Director 2023-09-01 1
Atul Dhawan Non-Executive - Independent Director 2024-05-16 2
Board Committees
CommitteeMembers
Audit Committee Bobby Kanubhai Parikh (Chairperson), Nicholas Robert Haggar, Atul Dhawan
Nomination and remuneration committee Naina Lal Kidwai (Chairperson), Ravi Rasendra Mazumdar, Rekha Mehrotra Menon
Stakeholders Relationship Committee Rekha Mehrotra Menon (Chairperson), Bobby Kanubhai Parikh, Ravi Rasendra Mazumdar
Risk Management Committee Bobby Kanubhai Parikh (Chairperson), Kiran Mazumdar Shaw, Siddhath Mittal, Eric Mazumdar, Nicholas Robert Haggar, Atul Dhawan
Corporate Social Responsibility Committee Naina Lal Kidwai (Chairperson), Ravi Rasendra Mazumdar, Siddhath Mittal, Eric Mazumdar, Rekha Mehrotra Menon, Nicholas Robert Haggar
Fund Raising Committee Kiran Mazumdar Shaw, Siddhath Mittal, Bobby Kanubhai Parikh

Group Structure of Biocon Limited

Biocon Limited has 6 subsidiary companies. This group structure data is as of FY 2022. The corporate group structure reflects Biocon Limited's business expansion strategy and organizational complexity.

6
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Syngene International Limited L85110KA1993PLC014937 -
Biocon Biologics Limited U24119KA2016FLC093936 -
Biocon Pharma Limited U24232KA2014PLC077036 -
Biocon Biosphere Limited U24304KA2019PLC130965 -
Biofusion Therapeutics Limited U73100KA2021PLC145487 -
Biocon Academy U80301KA2013NPL072272 -

Showing major subsidiaries. Total: 6.

Charges & Borrowings of Biocon Limited

Open charges
₹707.63 Cr
Satisfied charges
₹1,510.35 Cr
Breakdown by lending institutions
Others₹500.00 Cr
Hdfc Bank Limited₹197.50 Cr
Department of Biotechnology₹10.13 Cr
Latest charge details
DateLenderAmountStatus
28 Apr 2023 Others ₹500 Cr Open
07 Nov 2022 Hdfc Bank Limited ₹197.5 Cr Open
29 Jun 2011 Department of Biotechnology ₹4.43 Cr Open
12 Nov 2010 Department of Biotechnology ₹5.71 Cr Open
12 Feb 2023 Others ₹1,070 Cr Satisfied

Total charge records: 9 View all charges

Employees and EPFO Compliance at Biocon Limited

Biocon Limited has a workforce of 4,020 employees as of Apr 08, 2024.

Employee count
4,020
Active EPFO establishments
1
Employee growth
5.87%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Biocon Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Biocon Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Biocon Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Biocon Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Biocon Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Biocon Limited

MSME Payment Delays by Biocon Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Biocon Limited

Subsidiaries & Group Companies of Biocon Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Biocon Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Biocon Limited

MCA Filings & Documents of Biocon Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Biocon Limited

Charges
01 Oct 2025
A charge registered on 12 Feb 2023 via Charge ID 100825122 with Others was fully satisfied on 01 Oct 2025.
Activity
08 Aug 2025
Biocon Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Biocon Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Directors
21 Jun 2024
Mukesh Katapadi Kamath was appointed as a Cfo on 21 Jun 2024 & has been associated with this company since 2 years 18 days.
Directors
16 May 2024
Atul Dhawan was appointed as a Director on 16 May 2024 & has been associated with this company since 2 years 1 month.
Directors
01 Sep 2023
Nicholas Robert Haggar was appointed as a Director on 01 Sep 2023 & has been associated with this company since 2 years 10 months.

Recent News on Biocon Limited

Frequently Asked Questions about Biocon Limited

Biocon Limited is an active public limited company in the pharma sector based in Bengaluru, Karnataka, India. It was incorporated on 29 November 1978 (48+ years old) and is registered under CIN L24234KA1978PLC003417. Listed on BSE: 532523 and NSE: BIOCON. The company has 4,020 employees.

Biocon Limited reported revenue of ₹16,470 Cr for FY 2025 (up 5.00% YoY).

The current directors of Biocon Limited are:

The primary industry of Biocon Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Biocon Limited is listed on both BSE (code: 532523) and NSE (symbol: BIOCON).

Biocon Limited can be reached at the registered office: 20Th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100, or through the website biocon.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available